Business Wire

3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025

Share

3Degrees, a leading global climate solutions provider and certified B Corporation, is pleased to announce the appointment of Philippe Vedrenne as Chief Executive Officer (CEO), effective May 1, 2025. Vedrenne is moving into the role as 3Degrees’ current CEO and co-founder Steve McDougal steps away from leadership of the company. McDougal informed the Board of Directors last year that he would be retiring as CEO; he will maintain his involvement as a member of the Board.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422978066/en/

3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025

Vedrenne brings over two decades of global energy market experience operating across multiple continents. Most recently, at Engie, he oversaw trading and retail activities in North and South America for electricity and gas. In this position, he led efforts to bring utility-scale renewable energy solutions to the corporate market by combining wind, solar, and battery asset classes.

Vedrenne began his career in Europe at Gaz de France where he played a foundational role in the creation of Gasely, the trading business unit that evolved into Engie Global Markets, where he later became CEO. While running Engie’s natural gas midstream activities in Europe, he renegotiated the company’s long-term supply contracts to align them with markets, contributed to ensure European security of supply, and helped establish natural gas reverse flows to Ukraine in the wake of the Maidan uprisings and 2014 Russian-Ukrainian war. Before moving to the U.S. in 2021, Vedrenne led two significant projects for Engie: the development of renewable power purchase agreement (PPA) activities in Europe, and the net zero carbon project that defines Engie’s decarbonization ambition and trajectory to carbon neutrality by 2045.

“We are thrilled to welcome Philippe Vedrenne as the next CEO of 3Degrees,” said Dan Kalafatas, 3Degrees’ co-founder and Chair of the Board. “Our global search focused on selecting a new leader with the expertise to drive the next chapters of 3Degrees’ growth. Philippe brings a rare combination of global leadership experience, track record of success, service-leader orientation, and passion for bringing innovative decarbonization solutions to the world. The 3Degrees Board also wants to express deep gratitude to Steve McDougal. In his tenure as CEO, Steve spearheaded the company’s transformation from a small, North American-focused renewable energy commodity company into a leading global climate solutions provider advising some of the largest companies in the world.”

“I could not be more excited to assume the CEO role and help accelerate 3Degrees’ growth and our clients’ climate impact,” said Vedrenne. “The entire team is incredibly strong, with deep market and functional expertise. I’m looking forward to helping fuel the company’s continued expansion in both current and new markets, and to using our unique combination of market participation and client-centric focus to innovate new products and solutions. I’m honored to be asked to join such an exemplary organization, enabling me to work on a challenge of great urgency to us all.”

McDougal added, “Co-founding 3Degrees with Dan Kalafatas, and subsequently leading the company as CEO for the last ten years, has been one of the greatest privileges of my life. I am incredibly proud of what the 3Degrees team has built together over nearly two decades. I look forward to supporting the bright future for 3Degrees in my role on its Board of Directors and feel confident Philippe will be an excellent steward of the company as it expands its impact globally for our clients, partners, suppliers, employees, and the climate.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422978066/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye